Glaxo Smithkline working on new schizophrenia drug
UK drug major GlaxoSmithKline has provided an update on its drug in development to treat schizophrenia.
Talnetant, an NK3 antagonist, is being evaluated by GSK for schizophrenia. A Phase II trial is underway with a new formulation of the drug that permits higher dosing, and data are expected during next year. The agent may also provide cognitive benefits to schizophrenic patients.
Posted by szadmin at December 1, 2004 06:12 PM
More Information on
Schizophrenia Medications
